AI reshaping healthcare industry
来源:ChinaDaily
日期:2019-08-27 09:50:05
Applications are helping to deliver more efficient and accurate patient diagnosis
A doctor in a white coat sits in front of a computer screen displaying a lung CT scan, labeling the medical image - defining the normal elements and categorizing the abnormal ones.
She is not in a hospital, but a lab of Deepwise Healthcare, a leading Chinese medical AI startup that has offices in Beijing, Shanghai and Hangzhou, capital of Zhejiang province.
The annotations she makes on the scans, based on digital tools designed by the company, are essential to train the algorithms through deep-learning technology and enable AI to interpret scans and make diagnoses.
The promising prospects of medical AI applications to help deliver more accurate and comprehensive patient care through increased efficiency across clinical, financial, and operational domains have attracted a large number of investors and startups to the field.
Global revenue from the AI-related healthcare industry is expected to rise to $6.7 billion by 2021, and Chinese technology companies are aggressively moving into the field, according to consulting firm Frost and Sullivan.
China led the share of global investment and financing in the field of AI between 2013 and the first quarter of 2018, with 60 percent of the global total, followed by the United States with 29 percent and India with 5 percent, according to Future Health Index 2019, a report on digital health by health technology company Royal Philips.
"AI is widely believed to be able to greatly improve healthcare efficiency in China, and that is important because we have imbalanced medical resources among different regions and an acute shortage of doctors and nurses," said Qiao Xin, co-founder and CEO of Deepwise.
Founded in early 2017, Deepwise has obtained four rounds of funding, although details of the most recent C-round were not revealed. Previously, it raised a total of 300 million yuan ($42.77 million) during the A, A-plus and B rounds of funding.
The company's main products include AI medical aid diagnostic systems for early cancer detection, breast and lung scans, and stroke diagnosis, which are designed to improve hospital work efficiency and accuracy, alleviate the work burdens of often overworked medical professionals, and provide patients with a better overall hospital experience.
It has a team of more than 100 computer science engineers to develop AI solutions for healthcare, and controlled trials have shown that its medical imaging solutions' diagnosis accuracy for lung nodules is higher than the average for doctors, although it still lags behind that of elite physicians.
Qiao said although big hospitals in first-tier cities are more likely to use AI products compared with small hospitals in small cities and rural areas, it is obvious the latter are increasingly interested in medical AI applications as they are becoming more aware of the enhancements in patient care efficiency and accuracy that AI applications bring about.
Medical AI products are increasingly attractive to them because compared with big hospitals, smaller ones, especially those in counties and rural areas, find it difficult to recruit and retain talents, while AI solutions help to mitigate talent shortage problems, he said.
Among the more than 400 hospitals that use the company's AI products, about 70 percent are tertiary hospitals, but Qiao estimated the situation will reverse within a few years. China has a three-tier hospital grading system with the third grade being the highest.
Qiao explained that is because AI applications are often developed based on expertise from top hospitals' senior doctors, and thus can promote advanced disease treatment experiences from top hospitals to lower-level ones.
A visitor learns about Dr Lotus AI, an artificial intelligence-aided medical imaging system, at an exhibition in Qingdao, Shandong province, on June 11. [Photo by Yu Fangping/For China Daily]
In some cases, small hospitals can communicate with and seek direct help from a higher-level hospital if they use the same medical AI applications, he added.
Qiao also said the company is now working on projects to design AI-powered medical imaging products that focus on multiple diseases of different organs, instead of on a single disease or condition as they do now.
"Disease conditions can be complicated, and an integrated product with expertise on a specific organ is better able to tell the difference between different conditions to help doctors make an accurate diagnosis," Qiao said.
Shanghai-based Yitu Technology, a startup engaged in AI and facial recognition technologies, is also accelerating the application of AI technologies in the healthcare sector.
Yitu Healthcare, the healthcare arm of Yitu Technology, recently announced plans to invest 100 million yuan within the next five years and cooperate with hundreds of top medical institutions nationwide to accelerate the use of AI, in a bid to reduce doctors' workloa